Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus–Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season — New Vaccine Surveillance Network, October 2023–February 2024
Indexed incrossrefpubmed
Abstract
Respiratory syncytial virus (RSV) is the leading cause of hospitalization among infants in the United States. In August 2023, CDC's Advisory Committee on Immunization Practices recommended nirsevimab, a long-acting monoclonal antibody, for infants aged
Citation impact
198
total citations
- FWCI
- 69.64
- Percentile
- 100%
- References
- 9
Citations per year
Authors
46Topics & keywords
Topics
Keywords
- Medicine
- Pediatrics
- Lower respiratory tract infection
- Respiratory tract infections
- Vaccination
- Immunization
- Respiratory system
- Pneumovirinae
No related works found for this paper.
Funding
- PPfizer
- AAstraZeneca
- SSanofi
- NYNew York State Department of Health
- AOAssociation of American Medical Colleges
- PIPediatric Infectious Diseases Society
- BDBioFire Diagnostics
- IMInternational Maternal Pediatric Adolescent AIDS Clinical Trials Network
- MModerna
- SShionogi
- NINational Institutes of Health
- SPSanofi Pasteur
- AIAIDS Institute, New York State Department of Health
- NINational Institute of Allergy and Infectious Diseases
- DODivision of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases